138199-71-0

Basic information

• Product Name: (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1)
• Synonyms: levofloxacin hydrate;LEVOFLOXACIN HCL;(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1);LEVOFLOXACINH HYDROCHLORIDE;(S)-(-)-Ofloxacine;Levofloxacine;(-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hydrochloride;Levofloxacin (200 mg)
• CAS NO: 138199-71-0
• Molecular Formula: 2C₁₈H₂₀FN₃O₄*H₂O
• Molecular Weight: 397.83
• EINECS: 1806241-263-5
• Product Categories: Chiral Reagents;Antibiotic Explorer;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;TEQUIN
• Mol File: 138199-71-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 214-216°C
• Boiling Point: 571.5 °C at 760 mmHg
• Flash Point: 299.4 °C
• Appearance: pale yellow solid
• Density: 1.48 g/cm³
• Vapor Pressure: 6.7E-14mmHg at 25°C
• Storage Temp.: -20°C Freezer
• Solubility: Aqueous Base (Slightly), DMSO (Sparingly), Methanol (Slightly)
• CAS DataBase Reference: (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1)(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1)(138199-71-0)
• EPA Substance Registry System: (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1)(138199-71-0)

Safety Data

• Hazard Codes: N
• Statements: 50/53
• Safety Statements: 24/25-61-60
• WGK Germany: 3
• Hazardous Substances Data: 138199-71-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1) is used as an active pharmaceutical ingredient for the development of new drugs. Its unique chemical structure allows it to target specific biological pathways, making it a promising candidate for the treatment of various diseases.
Used in Antibacterial Applications:
In the field of antibacterial applications, (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1) is used as an antibiotic against gram-negative organisms. Its effectiveness in combating bacterial infections makes it a valuable addition to the arsenal of antibiotics available for treating various types of infections.
Used in Drug Delivery Systems:
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1) can also be utilized in the development of drug delivery systems. Its chemical properties may allow for the creation of novel drug carriers, enhancing the bioavailability and therapeutic outcomes of various medications.

InChI:InChI=1/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

Upstream product

• 177472-30-9 C₂₀H₂₄FN₃O₄ 
• 109-01-3 1-methyl-piperazine 
• 100986-89-8 levofloxacin Q-acid 

Relevant articles and documents

PROCESS FOR OBTAINING LEVOFLOXACIN FREE FROM SALTS

This invention relates to a process for obtaining levofloxacin free from salts. In this process the starting product used is the compound (V), alkaline hydrolysis of which within a water-(C1-C4)alcohol mixture, and subsequent neutralisation and separation of the salts, leads to levofloxacin free from salts. One characteristic of the process described is that no extractions are necessary in the final step of the process.

Methods for the purification of levofloxacin

Levofloxacin has been purified by dissolving levofloxacin in a polar solvent at an elevated temperature and crystallizing purified levofloxacin. Preferably, an antioxidant is added to increase the purity.